Dr. Reddy's Laboratories Ltd. and its subsidiaries have introduced Nerivio in Spain through its step-down subsidiary, Reddy Pharma Iberia S.A.

Nerivio is a United States Food and Drug Administration (USFDA)-licensed, CE-marked device that uses Remote Electrical Neuromodulation (REN) migraine treatment. This novel wearable technology is a drug-free and non-invasive treatment manufactured by Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, based in Israel and the United States.

Migraine is currently the sixth most prevalent pathology in the world and the second biggest cause of global disability. In Spain, more than 5 million people suffer from migraine (80 percent women) with a prevalence of 12 percent (17 percent in women). Migraine attacks limit the patient's work, family and social activities, and in up to 20-30 percent of cases, force the patient to remain in bed. In Spain, the average cost of migraine per patient per year is very high: EUR 12,970 for chronic migraine and EUR 5,041 for episodic migraine.

Nerivio is a non-invasive technology available to patients through doctor’s prescription and is intended for the acute and prophylactic (preventive) treatment of migraine with or without aura for adults and adolescents aged 12 years and older. Nerivio is placed on the upper arm and supported by a mobile app. Each Nerivio holds 18 treatment sessions of 45 minutes each.

For acute treatment, it should be used within 60 minutes of headache or aura onset and every other day for headache or aura prevention. The technology uses the mechanism of remote electrical neuromodulation (REN) to activate conditioned pain modulation (CPM), specifically by stimulating nociceptive nerve receptors located under the skin of the arm. This triggers a natural process of pain relief in the brainstem, causing a global pain inhibition effect that affects the source of migraine pain in the brain.

"Neuromodulation is a significant advancement in the treatment of migraine," says Dr. Patricia Pozo Rosich, Head of the Headache Unit at Vall d'Hebron University Hospital in Barcelona. Director of the Headache and Neurological Pain Research Laboratory at VHIR (Vall d'Hebron Research Institute), which belongs to the Universitat Autònoma de Barcelona (UAB).

"For decades, medication has been the mainstay of migraine treatment. However, with these medications, many patients experience side effects or limited efficacy. Neuromodulation technologies offer a necessary alternative that can also be complementary to pharmacological treatments. This technology modulates pain through stimulation of central descending inhibition. Nerivio could be especially recommended in patients where it is preferable not to use pharmacological treatments such as adolescents or women of childbearing age planning for pregnancy,” said Dr. Patricia Pozo Rosich.

Massimo Farioli, General Manager for Spain, Italy and France at Dr. Reddy's commented, "Bringing Nerivio to migraine patients in Spain underlines our commitment to meet unmet patient needs. The innovative drug-free treatment has the potential to improve the quality of life of migraine patients. It is placed on the upper arm and controlled by a mobile app, making it convenient, discreet, and portable. We believe this allows patients to focus on their daily activities more freely while wearing it, which addresses the clinical need to offer a more convenient migraine treatment that has not been available until now, with a significant impact on well-being and quality of life."

Proven in multiple clinical trials, Nerivio is a drug-free alternative suitable for a wide range of migraine patients, especially those seeking drug-free therapy, those who are unable to control their migraine with medication, or those with poor tolerance or contraindications to medication. In addition, sensitive populations such as adolescents, women of childbearing age and patients at risk of medication-overuse headaches may benefit from Nerivio.